MedKoo product information:

Alendronate sodium

Alendronate sodium is the sodium salt of alendronate, a second generation bisphosphonate and synthetic analog of pyrophosphate with bone anti-resorption activity. Alendronate sodium binds to and inhibits the activity of geranyltranstransferase (farnesyl pyrophosphate synthetase), an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which is important in the process of osteoclast turnover. As a result, osteoclast activity is inhibited and bone resorption and turnover are reduced. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

DRUG DESCRIPTION

FOSAMAX (alendronate sodium) is a bisphosphonate that acts as a specific inhibitor of osteoclast-mediated bone resorption. Bisphosphonates are synthetic analogs of pyrophosphate that bind to the hydroxyapatite found in bone.  Alendronate sodium is chemically described as (4-amino-1-hydroxybutylidene) bisphosphonic acid monosodium salt trihydrate. The empirical formula of alendronate sodium is C4H12NNaO7P2•3H2O and its formula weight is 325.12.   Alendronate sodium is a white, crystalline, nonhygroscopic powder. It is soluble in water, very slightly soluble in alcohol, and practically insoluble in chloroform.  Tablets FOSAMAX for oral administration contain 6.53, 13.05, 45.68, 52.21 or 91.37 mg of alendronate monosodium salt trihydrate, which is the molar equivalent of 5, 10, 35, 40 and 70 mg, respectively, of free acid, and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, croscarmellose sodium, and magnesium stearate. Tablets FOSAMAX 10 mg also contain carnauba wax. Each bottle of the oral solution contains 91.35 mg of alendronate monosodium salt trihydrate, which is the molar equivalent to 70 mg of free acid. Each bottle also contains the following inactive ingredients: sodium citrate dihydrate and citric acid anhydrous as buffering agents, sodium saccharin, artificial raspberry flavor, and purified water. Added as preservatives are sodium propylparaben 0.0225% and sodium butylparaben 0.0075%.

Mechanism of Action

Animal studies have indicated the following mode of action. At the cellular level, alendronate shows preferential localization to sites of bone resorption, specifically under osteoclasts. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active resorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Studies in mice on the localization of radioactive [3H]alendronate in bone showed about 10-fold higher uptake on osteoclast surfaces than on osteoblast surfaces. Bones examined 6 and 49 days after [3H]alendronate administration in rats and mice, respectively, showed that normal bone was formed on top of the alendronate, which was incorporated inside the matrix. While incorporated in bone matrix, alendronate is not pharmacologically active. Thus, alendronate must be continuously administered to suppress osteoclasts on newly formed resorption surfaces. Histomorphometry in baboons and rats showed that alendronate treatment reduces bone turnover (i.e., the number of sites at which bone is remodeled). In addition, bone formation exceeds bone resorption at these remodeling sites, leading to progressive gains in bone mass.

Current developer:   

 1: Salerno M, Cenni E, Fotia C, Avnet S, Granchi D, Castelli F, Micieli D, Pignatello R, Capulli M, Rucci N, Angelucci A, Del Fattore A, Teti A, Zini N, Giunti A, Baldini N. Bone-Targeted Doxorubicin-Loaded Nanoparticles as a Tool for the Treatment of Skeletal Metastases. Curr Cancer Drug Targets. 2010 Jun 25. [Epub ahead of print] PubMed PMID: 20578992.

2: Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, Lane DS, Manson JE, Snetselaar L, Yasmeen S, O'Sullivan MJ, Safford M, Hendrix SL, Wallace RB. Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women. J Clin Oncol. 2010 Jun 21. [Epub ahead of print] PubMed PMID: 20567009.

3: Ito K, Elkin EB, Girotra M, Morris MJ. Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med. 2010 May 18;152(10):621-9. PubMed PMID: 20479027.

4: Abrahamsen B. Bisphosphonate adverse effects, lessons from large databases. Curr Opin Rheumatol. 2010 Jul;22(4):404-9. PubMed PMID: 20473174.

5: Torres Martin de Rosales R, Finucane C, Foster J, Mather SJ, Blower PJ. 188Re(CO)3-dipicolylamine-alendronate: a new bisphosphonate conjugate for the radiotherapy of bone metastases. Bioconjug Chem. 2010 May 19;21(5):811-5. PubMed PMID: 20387897.

6: Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010 Apr;95(4):1555-65. Epub 2010 Feb 19. Review. PubMed PMID: 20173017.

7: Kotecha RS, Powers N, Lee SJ, Murray KJ, Carter T, Cole C. Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL). Pediatr Blood Cancer. 2010 Jul 1;54(7):934-40. PubMed PMID: 20127847.

8: Saad F, Abrahamsson PA, Miller K. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates. BJU Int. 2009 Dec;104(11):1573-9. Review. PubMed PMID: 20053188.

9: Cermak K, Shumelinsky F, Alexiou J, Gebhart MJ. Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy. Clin Orthop Relat Res. 2010 Jul;468(7):1991-6. Epub 2009 Dec 18. PubMed PMID: 20020334; PubMed Central PMCID: PMC2881993.

10: Adachi JD, Faraawi RY, O'Mahony MF, Nayar A, Massaad R, Evans JK, Yacik C. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study. Clin Ther. 2009 Aug;31(8):1747-53. PubMed PMID: 19808133.

11: Bivi N, Romanello M, Harrison R, Clarke I, Hoyle DC, Moro L, Ortolani F, Bonetti A, Quadrifoglio F, Tell G, Delneri D. Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection. Genome Biol. 2009;10(9):R93. Epub 2009 Sep 10. PubMed PMID: 19744312; PubMed Central PMCID: PMC2768982.

12: Kuroda I, Ueno M. [Biochemical markers of bone turnover. New aspect. Bone metabolic markers in prostatic carcinoma]. Clin Calcium. 2009 Aug;19(8):1170-7. Review. Japanese. PubMed PMID: 19638701.

13: Allen MR, Kubek DJ, Burr DB. Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. J Bone Miner Res. 2010 Jan;25(1):98-105. PubMed PMID: 19580463.

14: Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens). 2009 Apr-Jun;8(2):96-110. Review. PubMed PMID: 19570737.

15: Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, Placer J, Encabo G, Morote J. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. BJU Int. 2009 Dec;104(11):1637-40. Epub 2009 Jun 22. PubMed PMID: 19549260.

16: Bocanegra-Pérez S, Vicente-Barrero M, Sosa-Henríquez M, Gebaguer Blanco A, Knezevic M, Castellano-Navarro JM. [Osteonecrosis of the jaw secondary to oral alendronate: Report of three cases]. Rev Med Chil. 2009 Feb;137(2):275-9. Epub 2009 Jun 10. Spanish. PubMed PMID: 19543652.

17: O'Ryan FS, Khoury S, Liao W, Han MM, Hui RL, Baer D, Martin D, Liberty D, Lo JC. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg. 2009 Jul;67(7):1363-72. PubMed PMID: 19531404.

18: Susa M, Morii T, Yabe H, Horiuchi K, Toyama Y, Weissbach L, Hornicek FJ, Morioka H. Alendronate inhibits growth of high-grade chondrosarcoma cells. Anticancer Res. 2009 Jun;29(6):1879-88. PubMed PMID: 19528443.

19: Hikita H, Miyazawa K, Tabuchi M, Kimura M, Goto S. Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats. J Bone Miner Metab. 2009;27(6):663-72. Epub 2009 May 13. PubMed PMID: 19436946.

20: Panico A, Lupoli GA, Fonderico F, Marciello F, Martinelli A, Assante R, Lupoli G. Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate. Thyroid. 2009 May;19(5):437-42. PubMed PMID: 19415993.

21: Shaheen NJ. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009 Apr 23;360(17):1790-1; author reply 1791-2. PubMed PMID: 19391257.

22: Segal E, Pan H, Ofek P, Udagawa T, Kopecková P, Kopecek J, Satchi-Fainaro R. Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One. 2009;4(4):e5233. Epub 2009 Apr 21. PubMed PMID: 19381291; PubMed Central PMCID: PMC2667669.

23: Magliocca KR, Stavropoulos MF, Bhattacharyya I, Cohen DM. A compounded diagnosis: maxillary osteochemonecrosis in the setting of low dose radiotherapy. J Oral Maxillofac Surg. 2009 May;67(5):1138-40. PubMed PMID: 19375031.

24: Krishnan A, Arslanoglu A, Yildirm N, Silbergleit R, Aygun N. Imaging findings of bisphosphonate-related osteonecrosis of the jaw with emphasis on early magnetic resonance imaging findings. J Comput Assist Tomogr. 2009 Mar-Apr;33(2):298-304. PubMed PMID: 19346864.

25: Bryant ML, Worthington MA, Parsons K. Treatment of osteoporosis/osteopenia in pediatric leukemia and lymphoma. Ann Pharmacother. 2009 Apr;43(4):714-20. Epub 2009 Mar 31. Review. PubMed PMID: 19336653.

26: Long KA, Jackson JK, Yang C, Chehroudi B, Brunette DM, Burt HM. Controlled release of alendronate from polymeric films. J Biomater Sci Polym Ed. 2009;20(5-6):653-72. PubMed PMID: 19323882.

27: Mathew R, Dhillon V, Shepherd P. Systemic mastocytosis presenting as osteoporosis--a case report. Clin Rheumatol. 2009 Jul;28(7):865-6. Epub 2009 Mar 21. PubMed PMID: 19305945.

28: Junquera L, Gallego L, Pelaz A, Olay S. Oral bisphosphonates-associated osteonecrosis in rheumatoid arthritis. Med Oral Patol Oral Cir Bucal. 2009 Jun 1;14(6):E292-4. PubMed PMID: 19300372.

29: Miller K, Erez R, Segal E, Shabat D, Satchi-Fainaro R. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew Chem Int Ed Engl. 2009;48(16):2949-54. PubMed PMID: 19294707.

30: Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, Arlen PM, Wright JJ, Parnes H, Figg WD, Dahut WL. Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest. 2009 Feb;27(2):221-6. PubMed PMID: 19235596; PubMed Central PMCID: PMC2648132.

31: Mawardi H, Treister N, Richardson P, Anderson K, Munshi N, Faiella RA, Woo SB. Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws? J Oral Maxillofac Surg. 2009 Mar;67(3):593-601. PubMed PMID: 19231786.

32: Ito K, Hollenberg JP, Charlson ME. Using the osteoporosis self-assessment tool for referring older men for bone densitometry: a decision analysis. J Am Geriatr Soc. 2009 Feb;57(2):218-24. PubMed PMID: 19207137.

33: Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009 Jan 1;360(1):89-90. PubMed PMID: 19118315.

34: Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, Kogan R. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg. 2009 Jan;67(1):159-61. PubMed PMID: 19070762.

35: Farag N, Delbanco T, Strewler GJ. Update: A 64-year-old woman with primary hyperparathyroidism. JAMA. 2008 Nov 5;300(17):2044-5. PubMed PMID: 18984891.

36: Body JJ. [Update on treatment of postmenopausal osteoporosis]. Rev Med Brux. 2008 Sep;29(4):301-9. Review. French. PubMed PMID: 18949981.

37: Marx RE. Uncovering the cause of "phossy jaw" Circa 1858 to 1906: oral and maxillofacial surgery closed case files-case closed. J Oral Maxillofac Surg. 2008 Nov;66(11):2356-63. PubMed PMID: 18940506.

38: Yano A, Tsutsumi S, Soga S, Lee MJ, Trepel J, Osada H, Neckers L. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15541-6. PubMed PMID: 18840695; PubMed Central PMCID: PMC2563126.

39: Greenspan SL, Nelson JB, Trump DL, Wagner JM, Miller ME, Perera S, Resnick NM. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol. 2008 Sep 20;26(27):4426-34. PubMed PMID: 18802155; PubMed Central PMCID: PMC2653114.

40: Brandão CM, Lima MG, Silva AL, Silva GD, Guerra AA Jr, Acúrcio Fde A. Treatment of postmenopausal osteoporosis in women: a systematic review. Cad Saude Publica. 2008;24 Suppl 4:s592-606. Review. PubMed PMID: 18797733.

41: Tanriover MD, Oz SG, Sozen T, Kilicarslan A, Guven GS. Pregnancy- and lactation-associated osteoporosis with severe vertebral deformities: can strontium ranelate be a new alternative for the treatment? Spine J. 2009 Apr;9(4):e20-4. Epub 2008 Sep 14. PubMed PMID: 18790681.

42: Grewal VS, Fayans EP. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management. Todays FDA. 2008 Aug;20(8):38-41, 43-6. PubMed PMID: 18767452.

43: Pérez-Zúñiga FJ, Günther Sillero MA, Sillero A. Bisphosphonates activate the 5-fluorouracil/uracil phosphoribosyltransferase activity present in Saccharomyces cerevisiae cell extracts: implications for tumor treatments. Biochem Pharmacol. 2008 Oct 1;76(7):825-30. Epub 2008 Jul 23. PubMed PMID: 18706399.

44: Carranza Lira S. [Mandible osteonechrosis associated to bisfosfonates]. Ginecol Obstet Mex. 2007 Nov;75(11):655-60. Review. Spanish. PubMed PMID: 18697439.

45: Wong YK, Cheng JC. Bisphosphonate-related osteonecrosis of the jaws--report of 2 cases and strategies on prevention and management. Quintessence Int. 2008 Mar;39(3):195-201. PubMed PMID: 18618033.

46: Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, Kogan R. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Sep;106(3):389-91. Epub 2008 Jun 13. PubMed PMID: 18554944.

47: Lee WL, Chao HT, Cheng MH, Wang PH. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Maturitas. 2008 Jun 20;60(2):92-107. Epub 2008 Jun 4. Review. PubMed PMID: 18534794.

48: Kawahara T, Kobayashi T, Nishizawa K, Kobori G, Mitsumori K, Ogura K. Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer. Hinyokika Kiyo. 2008 Apr;54(4):261-6. PubMed PMID: 18516917.

49: Hansdóttir H. Raloxifene for older women: a review of the literature. Clin Interv Aging. 2008;3(1):45-50. Review. PubMed PMID: 18488877; PubMed Central PMCID: PMC2544368.

50: Gómez Font R, Martínez García ML, Olmos Martínez JM. Osteochemonecrosis of the jaws due to bisphosphonate treatments. Update. Med Oral Patol Oral Cir Bucal. 2008 May 1;13(5):E318-24. Review. PubMed PMID: 18449117.

51: Udvardy E, Redl P, Márton I. [Osteonecrosis of the jaw developing during bisphosphonate treatment]. Magy Onkol. 2008 Mar;52(1):81-7. Review. Hungarian. PubMed PMID: 18403302.

52: Sawada K, Morishige K, Mabuchi S, Ogata S, Kawase C, Sakata M, Kimura T. In vitro and in vivo assays to analyze the contribution of Rho kinase in angiogenesis. Methods Enzymol. 2008;439:395-412. PubMed PMID: 18374179.

53: Tuomela JM, Valta MP, Väänänen K, Härkönen PL. Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice. BMC Cancer. 2008 Mar 28;8:81. PubMed PMID: 18371232; PubMed Central PMCID: PMC2294135.

54: Watts NB, Marciani RD. Osteonecrosis of the jaw. South Med J. 2008 Feb;101(2):160-5. Review. PubMed PMID: 18364618.

55: Cohen A, Fleischer JB, Johnson MK, Brown IN, Joe AK, Hershman DL, McMahon DJ, Silverberg SJ. Prevention of bone loss after withdrawal of tamoxifen. Endocr Pract. 2008 Mar;14(2):162-7. PubMed PMID: 18308653.

56: Alves AP, Pessoa Cdo O, Costa-Lotufo L, Moraes Filho MO. Radiographic and histological evaluation of bisphosphonate alendronate and metotrexate effects on rat mandibles inoculated with Walker 256 carcinosarcoma. Acta Cir Bras. 2007 Nov-Dec;22(6):457-64. PubMed PMID: 18235934.

57: Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007 Nov;1117:209-57. Review. PubMed PMID: 18056045.

58: Vieillard MH, Maes JM, Penel G, Facon T, Magro L, Bonneterre J, Cortet B. Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. Joint Bone Spine. 2008 Jan;75(1):34-40. Epub 2007 Aug 31. PubMed PMID: 17981488.

59: Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res. 2007 Nov;86(11):1022-33. Review. PubMed PMID: 17959891.

60: Lethaby C, Wiernikowski J, Sala A, Naronha M, Webber C, Barr RD. Bisphosphonate therapy for reduced bone mineral density during treatment of acute lymphoblastic leukemia in childhood and adolescence: a report of preliminary experience. J Pediatr Hematol Oncol. 2007 Sep;29(9):613-6. PubMed PMID: 17805035.

61: Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf. 2007;30(9):755-63. Review. PubMed PMID: 17722968.

62: Body JJ, Bergmann P, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, Reginster JY, Rozenberg S, Kaufman JM. Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club. Osteoporos Int. 2007 Nov;18(11):1439-50. Epub 2007 Aug 10. Review. PubMed PMID: 17690930.

63: Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB. Malignancy-related hypercalcemia developing on a bisphosphonate but responding to calcitonin. Clin Lung Cancer. 2007 Jul;8(7):434-5. PubMed PMID: 17681097.

64: Heras Rincón I, Zubillaga Rodríguez I, Castrillo Tambay M, Montalvo Moreno JJ. Osteonecrosis of the jaws and bisphosphonates. Report of fifteen cases. Therapeutic recommendations. Med Oral Patol Oral Cir Bucal. 2007 Aug 1;12(4):E267-71. PubMed PMID: 17664910.

65: Malden NJ, Pai AY. Oral bisphosphonate associated osteonecrosis of the jaws: three case reports. Br Dent J. 2007 Jul 28;203(2):93-7. PubMed PMID: 17660780.

66: Lai TJ, Hsu SF, Li TM, Hsu HC, Lin JG, Hsu CJ, Chou MC, Lee MC, Yang SF, Fong YC. Alendronate inhibits cell invasion and MMP-2 secretion in human chondrosarcoma cell line. Acta Pharmacol Sin. 2007 Aug;28(8):1231-5. PubMed PMID: 17640487.

67: Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int. 2007 Oct;18(10):1363-70. Epub 2007 Jun 28. PubMed PMID: 17598065.

68: Pritchard KI. Bisphosphonates: are they standard of care for the treatment of breast cancer? Br J Cancer. 2007 Jun 18;96(12):1781-2. PubMed PMID: 17565339; PubMed Central PMCID: PMC2359974.

69: Khosa AD, Nayyar MS, Beirne JC. Osteochemonecrosis of jaws and bisphosphonates. Ir Med J. 2007 Mar;100(3):410-1. Review. PubMed PMID: 17491545.

70: Kuehn BM. Contrast agent may aid cancer detection. JAMA. 2007 May 9;297(18):1969. PubMed PMID: 17488956.

71: Dalle Carbonare L, Valenti MT, Bertoldo F, Fracalossi A, Balducci E, Azzarello G, Vinante O, Lo Cascio V. Amino-bisphosphonates decrease hTERT gene expression in breast cancer in vitro. Aging Clin Exp Res. 2007 Apr;19(2):91-6. PubMed PMID: 17446718.

72: Meadows ES, Klein R, Rousculp MD, Smolen L, Ohsfeldt RL, Johnston JA. Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Womens Health. 2007 Apr 17;7:6. PubMed PMID: 17439652; PubMed Central PMCID: PMC1866224.

73: Tau C, Russo R. [Severe osteoporosis with vertebral crushes in juvenile dermatomyositis. Effect of oral alendronate therapy]. Medicina (B Aires). 2007;67(1):53-6. Spanish. PubMed PMID: 17408022.

74: Gering A, Grange L, Villier C, Woeller A, Mallaret M. [Bisphosphonates-associated osteonecrosis of the jaw: review on reported cases]. Therapie. 2007 Jan-Feb;62(1):49-54. Epub 2007 Mar 21. French. PubMed PMID: 17374348.

75: Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med. 2007 Mar 20;146(6):416-24. PubMed PMID: 17371886.

76: Summaries for patients. Preventing bone loss in men with prostate cancer. Ann Intern Med. 2007 Mar 20;146(6):I72. PubMed PMID: 17371883.

77: Terashima T, Hiramatsu K, Shimatani A, Matsuda M, Ogino H, Satomura Y, Noda Y. An esophageal ulcer mimicking advanced esophageal cancer in a patient on alendronate sodium treatment for osteoporosis. Endoscopy. 2006;38 Suppl 2:E37. PubMed PMID: 17366400.

78: Molinuevo MS, Bruzzone L, Cortizo AM. Alendronate induces anti-migratory effects and inhibition of neutral phosphatases in UMR106 osteosarcoma cells. Eur J Pharmacol. 2007 May 7;562(1-2):28-33. Epub 2007 Feb 8. PubMed PMID: 17341419.

79: Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007 Mar;65(3):415-23. PubMed PMID: 17307586.

80: Hashimoto K, Morishige K, Sawada K, Tahara M, Shimizu S, Ogata S, Sakata M, Tasaka K, Kimura T. Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem Biophys Res Commun. 2007 Mar 9;354(2):478-84. Epub 2007 Jan 11. PubMed PMID: 17240356.

81: Edwards CM, Mueller G, Roelofs AJ, Chantry A, Perry M, Russell RG, Van Camp B, Guyon-Gellin Y, Niesor EJ, Bentzen CL, Vanderkerken K, Croucher PI. Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. Int J Cancer. 2007 Apr 15;120(8):1657-63. PubMed PMID: 17230522.

82: Briot K, Trémollières F, Thomas T, Roux C; Comité scientifique du GRIO. How long should patients take medications for postmenopausal osteoporosis? Joint Bone Spine. 2007 Jan;74(1):24-31. Epub 2006 Dec 4. Review. PubMed PMID: 17223374.

83: Benhamou CL. Effects of osteoporosis medications on bone quality. Joint Bone Spine. 2007 Jan;74(1):39-47. Epub 2006 Nov 28. Review. PubMed PMID: 17196423.

84: Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L Jr, Stock JL. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone. 2007 Apr;40(4):843-51. Epub 2006 Dec 19. PubMed PMID: 17182297.

85: Merigo E, Manfredi M, Meleti M, Guidotti R, Ripasarti A, Zanzucchi E, D'Aleo P, Corradi D, Corcione L, Sesenna E, Ferrari S, Poli T, Bonaninil M, Vescovi P. Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed. 2006 Aug;77(2):109-17. PubMed PMID: 17172192.

86: Nastro E, Musolino C, Allegra A, Oteri G, Cicciù M, Alonci A, Quartarone E, Alati C, De Ponte FS. Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. Acta Haematol. 2007;117(3):181-7. Epub 2006 Dec 12. PubMed PMID: 17164581.

87: Wu SL, Jones E, Gulley JL, Arlen PM, Chen CC, Figg WD, Dahut WL. Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone. BJU Int. 2007 Mar;99(3):525-8. Epub 2006 Nov 28. PubMed PMID: 17155971.

88: Bobba RS, Beattie K, Parkinson B, Kumbhare D, Adachi JD. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug Saf. 2006;29(12):1133-52. Review. PubMed PMID: 17147460.

89: Kuttikat A, Keat A, Hughes R, Hakim A, Chakravarty K. A case of polymyalgia rheumatica, microscopic polyangiitis, and B-cell lymphoma. Nat Clin Pract Rheumatol. 2006 Dec;2(12):686-90; quiz 1p following 691. PubMed PMID: 17133254.

90: Bruder JM, Ma JZ, Wing N, Basler J, Katselnik D. Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy. J Clin Densitom. 2006 Oct-Dec;9(4):431-7. Epub 2006 Sep 6. PubMed PMID: 17097529.

91: Ozen M, Karaahmet F, Aydin K, Sarici F, Altundag K. Bisphosphonates may also be effective in the management of non-skeletal metastases in hormone receptor positive breast cancer. Med Hypotheses. 2007;68(3):714. Epub 2006 Oct 24. PubMed PMID: 17064852.

92: Perez EA, Weilbaecher K. Aromatase inhibitors and bone loss. Oncology (Williston Park). 2006 Aug;20(9):1029-39; discussion 1039-40, 1042, 1048. Review. PubMed PMID: 16986348; PubMed Central PMCID: PMC2693896.

93: Gołkowski F, Barczyński M, Buziak-Bereza M, Huszno B, Cichoń S. [New horizons for increased sensitivity of radionuclide imaging in primary hyperparathyroidism]. Przegl Lek. 2006;63(2):64-7. Polish. PubMed PMID: 16967712.

94: Berry S, Waldron T, Winquist E, Lukka H. The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials. Can J Urol. 2006 Aug;13(4):3180-8. Review. PubMed PMID: 16952326.

95: Hussein WI, El-Maghraby TA, Al-Sanea O. Hyperfunctioning intrathyroidal parathyroid carcinoma. Saudi Med J. 2006 Aug;27(8):1226-9. PubMed PMID: 16883457.

96: Ponte Fernández N, Estefania Fresco R, Aguirre Urizar JM. Bisphosphonates and oral pathology I. General and preventive aspects. Med Oral Patol Oral Cir Bucal. 2006 Aug 1;11(5):E396-400. Review. English, Spanish. PubMed PMID: 16878067.

97: Marunick M, Gordon S. Prosthodontic treatment during active osteonecrosis related to radiation and bisphosphonate therapy: a clinical report. J Prosthet Dent. 2006 Jul;96(1):7-12. PubMed PMID: 16872925.

98: Tragiannidis A, Athanassiadou F, Papageorgiou T, Petsatodis G. Severe skeletal complications in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2006 Sep;23(6):523-5; author reply 527-8. PubMed PMID: 16849284.

99: Goeree R, Blackhouse G, Adachi J. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada. Curr Med Res Opin. 2006 Jul;22(7):1425-36. PubMed PMID: 16834841.

100: Jarnbring F, Ulmner M, Blomlöf J, Ljungman P. [Diphosphonates can cause necrosis of the jaw. Patients with malignant skeletal diseases are at risk]. Lakartidningen. 2006 May 31-Jun 6;103(21-22):1741-3. Swedish. PubMed PMID: 16826719.

101: Capalbo S, Delia M, Diomede D, Dargenio M, Chiefa A, Favia G, Liso V. Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients. Int J Hematol. 2006 Jun;83(5):439-42. PubMed PMID: 16787865.

102: Verdijk R, Franke HR, Wolbers F, Vermes I. Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett. 2007 Feb 8;246(1-2):308-12. Epub 2006 Apr 18. PubMed PMID: 16621245.

103: Teut M, Warning A. [Bone metastases in breast carcinoma]. Forsch Komplementmed. 2006 Feb;13(1):46-8. Epub 2006 Jan 3. German. PubMed PMID: 16582551.

104: Guay DR. Ibandronate: a new oral bisphosphonate for postmenopausal osteoporosis. Consult Pharm. 2005 Dec;20(12):1036-55. PubMed PMID: 16548678.

105: Holmes-Walker DJ, Woo H, Gurney H, Do VT, Chipps DR. Maintaining bone health in patients with prostate cancer. Med J Aust. 2006 Feb 20;184(4):176-9. Review. PubMed PMID: 16489902.

106: Farrugia MC, Summerlin DJ, Krowiak E, Huntley T, Freeman S, Borrowdale R, Tomich C. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope. 2006 Jan;116(1):115-20. Review. PubMed PMID: 16481822.

107: Uebelhart B, Rizzoli R. [Osteoporosis treatment]. Rev Med Suisse. 2006 Jan 4;2(47):47-51. Review. French. PubMed PMID: 16465945.

108: Wiernikowski JT, Barr RD, Webber C, Guo CY, Wright M, Atkinson SA. Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study. J Oncol Pharm Pract. 2005 Jun;11(2):51-6. PubMed PMID: 16460605.

109: Hoefert S, Eufinger H. [Osteonecrosis of the jaws as a possible adverse effect of the use of bisphosphonates]. Mund Kiefer Gesichtschir. 2005 Jul;9(4):233-8. German. PubMed PMID: 16395774.

110: Sawka AM, Ioannidis G, Papaioannou A, Thabane L, Olszynski WP, Brown JP, Hanley DA, Murray TM, Josse RG, Sebaldt RJ, Petrie A, Tenenhouse A, Goldsmith CH, Boulos P, Kouroukis T, Adachi JD. Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis? J Obstet Gynaecol Can. 2005 Aug;27(8):759-64. PubMed PMID: 16287007.

111: Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005 Nov;63(11):1567-75. PubMed PMID: 16243172.

112: Sarathy AP, Bourgeois SL Jr, Goodell GG. Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports. J Endod. 2005 Oct;31(10):759-63. Erratum in: J Endod. 2005 Nov;31(11):835-6. PubMed PMID: 16186759.

113: Knight LA, Conroy M, Fernando A, Polak M, Kurbacher CM, Cree IA. Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay. Anticancer Drugs. 2005 Oct;16(9):969-76. PubMed PMID: 16162973.

114: Suzuki Y, Ishibashi Y, Omura N, Kawasaki N, Kashiwagi H, Yanaga K, Abo M, Urashima M. Alendronate improves vitamin D-resistant osteopenia triggered by gastrectomy in patients with gastric cancer followed long term. J Gastrointest Surg. 2005 Sep-Oct;9(7):955-60. PubMed PMID: 16137591.

115: Inoue R, Matsuki NA, Jing G, Kanematsu T, Abe K, Hirata M. The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells. Br J Pharmacol. 2005 Nov;146(5):633-41. PubMed PMID: 16100524; PubMed Central PMCID: PMC1751194.

116: Muller S, Migianu E, Lecouvey M, Kraemer M, Oudar O. Alendronate inhibits proliferation and invasion of human epidermoid carcinoma cells in vitro. Anticancer Res. 2005 Jul-Aug;25(4):2655-60. PubMed PMID: 16080508.

117: Peña de la Vega L, Fervenza FC, Lager D, Habermann T, Leung N. Acute granulomatous interstitial nephritis secondary to bisphosphonate alendronate sodium. Ren Fail. 2005;27(4):485-9. PubMed PMID: 16060139.

118: Dalle Carbonare L, Valenti MT, Azzarello G, Balducci E, Crepaldi G, Realdi G, Vinante O, Giannini S. Bisphosphonates decrease telomerase activity and hTERT expression in MCF-7 breast cancer cells. Mol Cell Endocrinol. 2005 Aug 30;240(1-2):23-31. PubMed PMID: 15978718.

119: Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol. 2005 Jul;17(4):462-6. Review. PubMed PMID: 15956844.

120: Onuma E, Azuma Y, Saito H, Tsunenari T, Watanabe T, Hirabayashi M, Sato K, Yamada-Okabe H, Ogata E. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors. Clin Cancer Res. 2005 Jun 1;11(11):4198-203. PubMed PMID: 15930357.

121: Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess. 2005 Jun;9(22):1-160. Review. PubMed PMID: 15929857.

122: Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer. 2005 Jul 1;104(1):83-93. PubMed PMID: 15929121.

123: Gaudio A, Morabito N. Pharmacological management of severe postmenopausal osteoporosis. Drugs Aging. 2005;22(5):405-17. Review. PubMed PMID: 15903353.

124: Ibáñez R, Gutierrez R, Fito C, del Val N, Loza E. Chondrosarcoma in Paget's disease of bone. Clin Exp Rheumatol. 2005 Mar-Apr;23(2):275. PubMed PMID: 15895907.

125: Vaisman DN, McCarthy AD, Cortizo AM. Bone-specific alkaline phosphatase activity is inhibited by bisphosphonates: role of divalent cations. Biol Trace Elem Res. 2005 May;104(2):131-40. PubMed PMID: 15894813.

126: Makras P, Kaltsas GA, Athanasoulis T, Papadogias D, Zografos GN, Kontogeorgos G, Borboli N, Piaditis G. Treatment with oral biphosphonates can increase the sensitivity of sestamibi radionuclide imaging in patients with primary hyperparathyroidism. Int J Clin Pharmacol Res. 2005;25(1):19-28. PubMed PMID: 15864874.

127: Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust. 2005 Apr 18;182(8):413-5. PubMed PMID: 15850439.

128: Demirkan B, Başkan Z, Alacacioğlu A, Görken IB, Bekiş R, Ada E, Osma E, Alakavuklar M. False negative bone scintigraphy in a patient with primary breast cancer: a possible transient phenomenon of bisphosphonate (alendronate) treatment. Tumori. 2005 Jan-Feb;91(1):77-80. PubMed PMID: 15850010.

129: Robinson WR, Luck M, Omar H, Blades N, Morris K, Coscia J. A pilot study of bone density loss in menopausal women treated with chemotherapy for cancer. Support Care Cancer. 2005 Aug;13(8):663-7. Epub 2005 Apr 13. PubMed PMID: 15827728.

130: Onuma E, Tsunenari T, Saito H, Sato K, Yamada-Okabe H, Ogata E. Parathyroid hormone-related protein (PTHrP) as a causative factor of cancer-associated wasting: possible involvement of PTHrP in the repression of locomotor activity in rats bearing human tumor xenografts. Int J Cancer. 2005 Sep 1;116(3):471-8. PubMed PMID: 15800941.

131: Figg WD, Liu Y, Arlen P, Gulley J, Steinberg SM, Liewehr DJ, Cox MC, Zhai S, Cremers S, Parr A, Yang X, Chen CC, Jones E, Dahut WL. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol. 2005 Mar;173(3):790-6. PubMed PMID: 15711271.

132: Hashimoto K, Morishige K, Sawada K, Tahara M, Kawagishi R, Ikebuchi Y, Sakata M, Tasaka K, Murata Y. Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model. Cancer Res. 2005 Jan 15;65(2):540-5. PubMed PMID: 15695397.

133: Eshed V, Dresner J, Gross D. Osteoporosis and amenorrhea in a young patient with von Hippel-Lindau disease. Isr Med Assoc J. 2005 Jan;7(1):48-9. PubMed PMID: 15658149.

134: Kitano M, Ogata A, Sekiguchi M, Hamano T, Sano H. Biphasic anti-osteoclastic action of intravenous alendronate therapy in multiple myeloma bone disease. J Bone Miner Metab. 2005;23(1):48-52. PubMed PMID: 15616894.

135: Kabelitz D, Wesch D, Pitters E, Zöller M. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J Immunol. 2004 Dec 1;173(11):6767-76. PubMed PMID: 15557170.

136: Fadanelli ME, Bone HG. Combining bisphosphonates with hormone therapy for postmenopausal osteoporosis. Treat Endocrinol. 2004;3(6):361-9. Review. PubMed PMID: 15511130.

137: Vorotnjak M, Boos J, Lanvers-Kaminsky C. In vitro toxicity of bisphosphonates on human neuroblastoma cell lines. Anticancer Drugs. 2004 Sep;15(8):795-802. PubMed PMID: 15494642.

138: Saunders Y, Ross JR, Broadley KE, Edmonds PM, Patel S; Steering Group. Systematic review of bisphosphonates for hypercalcaemia of malignancy. Palliat Med. 2004 Jul;18(5):418-31. Review. PubMed PMID: 15332420.

139: Sevcik MA, Luger NM, Mach DB, Sabino MA, Peters CM, Ghilardi JR, Schwei MJ, Röhrich H, De Felipe C, Kuskowski MA, Mantyh PW. Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. Pain. 2004 Sep;111(1-2):169-80. PubMed PMID: 15327821.

140: Farese JP, Ashton J, Milner R, Ambrose LL, Van Gilder J. The effect of the bisphosphonate alendronate on viability of canine osteosarcoma cells in vitro. In Vitro Cell Dev Biol Anim. 2004 Mar-Apr;40(3-4):113-7. PubMed PMID: 15311969.

141: Quattrocchi E, Kourlas H. Teriparatide: a review. Clin Ther. 2004 Jun;26(6):841-54. Review. PubMed PMID: 15262455.

142: Hershman D, Narayanan R. Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer. Curr Oncol Rep. 2004 Jul;6(4):277-84. Review. PubMed PMID: 15161581.

143: Fontanges E, Fontana A, Delmas P. Osteoporosis and breast cancer. Joint Bone Spine. 2004 Mar;71(2):102-10. Review. PubMed PMID: 15116704.

144: Stepan JJ, Alenfeld F, Boivin G, Feyen JH, Lakatos P. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr Regul. 2003 Dec;37(4):225-38. Review. PubMed PMID: 15106819.

145: Andela VB. Correspondence Re S. S. Virtanen et al., Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002;62:2708-14. Re K. Sawada et al., Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho. Cancer Res 2002;62:6015-20. Cancer Res. 2004 Apr 15;64(8):2934-5; author reply 2935-6. PubMed PMID: 15087415.

146: Cheng YY, Huang L, Lee KM, Li K, Kumta SM. Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer. 2004 May;42(5):410-5. PubMed PMID: 15049011.

147: Arlen PM, Figg WD, Gulley J, Cox MC, Linehan WM, Dahut W. National Cancer Institute intramural approach to advanced prostate cancer. Clin Prostate Cancer. 2002 Dec;1(3):153-62. PubMed PMID: 15046690.

148: Cheng YY, Huang L, Lee KM, Xu JK, Zheng MH, Kumta SM. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int. 2004 Jul;75(1):71-7. PubMed PMID: 15037971.

149: Waltman NL, Twiss JJ, Ott CD, Gross GJ, Lindsey AM, Moore TE, Berg K. Testing an intervention for preventing osteoporosis in postmenopausal breast cancer survivors. J Nurs Scholarsh. 2003;35(4):333-8. PubMed PMID: 14735675.

150: Unson CG, Siccion E, Gaztambide J, Gaztambide S, Mahoney Trella P, Prestwood K. Nonadherence and osteoporosis treatment preferences of older women: a qualitative study. J Womens Health (Larchmt). 2003 Dec;12(10):1037-45. PubMed PMID: 14709192.

151: Uebelhart D, Frey D, Frey-Rindova P, Goerres G, Michel BA. [Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium]. Z Rheumatol. 2003 Dec;62(6):512-7. Review. German. PubMed PMID: 14685711.

152: Alvarez E, Westmore M, Galvin RJ, Clapp CL, Considine EL, Smith SJ, Keyes K, Iversen PW, Delafuente DM, Sulaimon S, Zambrano C, Ma L, Sato M, Martin TJ, Teicher BA, Galbreath EJ. Properties of bisphosphonates in the 13762 rat mammary carcinoma model of tumor-induced bone resorption. Clin Cancer Res. 2003 Nov 15;9(15):5705-13. PubMed PMID: 14654555.

153: Jeong JM, Chung JK. Therapy with 188Re-labeled radiopharmaceuticals: an overview of promising results from initial clinical trials. Cancer Biother Radiopharm. 2003 Oct;18(5):707-17. Review. PubMed PMID: 14629819.

154: Shoemaker JR, Klemes AB. Alternate options to hormone replacement therapy for osteoporosis. J Am Osteopath Assoc. 2003 Oct;103(10 Suppl 6):S1-5. Erratum in: J Am Osteopath Assoc. 2003 Nov;103(11):502. PubMed PMID: 14620078.

155: Mullins CD, Ohsfeldt RL. Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy. J Manag Care Pharm. 2003 Mar-Apr;9(2):150-8. PubMed PMID: 14613344.

156: Andela VB, Pirri M, Schwarz EM, Puzas EJ, O'Keefe RJ, Rosenblatt JD, Rosier RN. The mevalonate synthesis pathway as a therapeutic target in cancer. Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S59-66. Review. PubMed PMID: 14600593.

157: Hoshiro M, Harada T, Iwai H, Miyatake T, Nishimura A, Ohno Y, Aoki N. Two cases of monostotic Paget's disease: effects of bisphosphonate. Endocr J. 2003 Aug;50(4):385-92. PubMed PMID: 14599111.

158: Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B. Early discontinuation of treatment for osteoporosis. Am J Med. 2003 Aug 15;115(3):209-16. PubMed PMID: 12947959.

159: Bhansali A, Kataria RN, Dutta P, Saha MM, Singh P, Dash RJ. Parathyroid carcinoma: difficult management options. Indian J Cancer. 2002 Jul-Sep;39(3):119-22. PubMed PMID: 12928568.

160: Eastell R. Management of osteoporosis due to ovarian failure. Med Pediatr Oncol. 2003 Sep;41(3):222-7. Review. PubMed PMID: 12868123.

161: Salomo M, Jurlander J, Nielsen LB, Gimsing P. How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics. Br J Haematol. 2003 Jul;122(2):202-10. PubMed PMID: 12846887.

162: Halleen JM. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Anticancer Res. 2003 Mar-Apr;23(2A):1027-9. PubMed PMID: 12820342.

163: Reid IR. Bisphosphonates: new indications and methods of administration. Curr Opin Rheumatol. 2003 Jul;15(4):458-63. Review. PubMed PMID: 12819475.

164: Smith MR. Management of treatment-related osteoporosis in men with prostate cancer. Cancer Treat Rev. 2003 Jun;29(3):211-8. PubMed PMID: 12787715.

165: Inaoui R, Petit B, Jaccard A, Bertin P, Trèves R. Aggressive systemic mastocytosis. Joint Bone Spine. 2003 Feb;70(1):64-6. PubMed PMID: 12639621.

166: Nakatsuka K. [Development of bisphosphonates]. Nippon Rinsho. 2003 Feb;61(2):219-25. Review. Japanese. PubMed PMID: 12638211.

167: Smith MR. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging. 2003;20(3):175-83. Review. PubMed PMID: 12578398.

168: Smith MR. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer. 2003 Feb 1;97(3 Suppl):789-95. Review. PubMed PMID: 12548577.

169: Grimes DA, Lobo RA. Perspectives on the Women's Health Initiative trial of hormone replacement therapy. Obstet Gynecol. 2002 Dec;100(6):1344-53. Review. PubMed PMID: 12468183.

170: Sawada K, Morishige K, Tahara M, Kawagishi R, Ikebuchi Y, Tasaka K, Murata Y. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho. Cancer Res. 2002 Nov 1;62(21):6015-20. PubMed PMID: 12414621.

171: Riis BJ, Lehmann HJ, Christiansen C. Norethisterone acetate in combination with estrogen: effects on the skeleton and other organs. A review. Am J Obstet Gynecol. 2002 Oct;187(4):1101-16. Review. PubMed PMID: 12389012.

172: Paterson AH. Bisphosphonates: biological response modifiers in breast cancer. Clin Breast Cancer. 2002 Aug;3(3):206-16; discussion 217-8. Review. PubMed PMID: 12196279.

173: Hlavaty T, Lukac L, Vyskocil M, Galbavy S. Heterotopic pancreas in gastric antrum with macroscopic appearance of gastric polyp. Bratisl Lek Listy. 2002;103(3):117-20. PubMed PMID: 12190044.

174: Ogata A, Kitano M, Hashimoto N, Iwasaki T, Hamano T, Kakishita E. Chemotherapy did not enhance the anti-osteolytic effects of bisphosphonate in multiple myeloma bone disease. J Bone Miner Metab. 2002;20(4):240-2. PubMed PMID: 12115071.

175: Rubin MR, Bilezikian JP. The potential of parathyroid hormone as a therapy for osteoporosis. Int J Fertil Womens Med. 2002 May-Jun;47(3):103-15. Review. PubMed PMID: 12081255.

176: Atoyebi W, Brown M, Wass J, Littlewood TJ, Hatton C. Lymphoplasmacytoid lymphoma presenting as severe osteoporosis. Am J Hematol. 2002 May;70(1):77-80. PubMed PMID: 11994987.

177: Heikkilä P, Teronen O, Moilanen M, Konttinen YT, Hanemaaijer R, Laitinen M, Maisi P, van der Pluijm G, Bartlett JD, Salo T, Sorsa T. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs. 2002 Mar;13(3):245-54. PubMed PMID: 11984068.

178: Virtanen SS, Väänänen HK, Härkönen PL, Lakkakorpi PT. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res. 2002 May 1;62(9):2708-14. PubMed PMID: 11980672.

179: Grady D. A 60-year-old woman trying to discontinue hormone replacement therapy. JAMA. 2002 Apr 24;287(16):2130-7. PubMed PMID: 11966388.

180: Andela VB, Rosenblatt JD, Schwarz EM, Puzas EJ, O'Keefe RJ, Rosier RN. Synergism of aminobisphosphonates and farnesyl transferase inhibitors on tumor metastasis. Clin Orthop Relat Res. 2002 Apr;(397):228-39. PubMed PMID: 11953614.

181: Stepensky D, Golomb G, Hoffman A. Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats. J Pharm Sci. 2002 Feb;91(2):508-16. PubMed PMID: 11835209.

182: Duques P, Araújo RS, de Amorim WP. [Esophagus-enteric anastomosis ulceration caused by alendronate]. Arq Gastroenterol. 2001 Apr-Jun;38(2):129-31. Portuguese. PubMed PMID: 11793943.

183: Vasikaran SD. Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem. 2001 Nov;38(Pt 6):608-23. Review. PubMed PMID: 11732644.

184: Rubin MR, Livolsi VA, Bandeira F, Caldas G, Bilezikian JP. Tc99m-sestamibi uptake in osteitis fibrosa cystica simulating metastatic bone disease. J Clin Endocrinol Metab. 2001 Nov;86(11):5138-41. PubMed PMID: 11701666.

185: Carrasquillo JA, Whatley M, Dyer V, Figg WD, Dahut W. Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning. J Nucl Med. 2001 Sep;42(9):1359-63. PubMed PMID: 11535725.

186: Das H, Wang L, Kamath A, Bukowski JF. Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood. 2001 Sep 1;98(5):1616-8. PubMed PMID: 11520816.

187: Wang XM, Yu SF, Yang ZP. Apoptosis of osteoclast-like cells induced by alendronate is related to Fas gene expression. Chin J Dent Res. 2000 Aug;3(2):26-32. PubMed PMID: 11314515.

188: Moore HC. Managing menopause after breast cancer: balancing risks and benefits. Cleve Clin J Med. 2001 Mar;68(3):243-8. PubMed PMID: 11263852.

189: Arteaga de Murphy C, Ferro-Flores G, Pedraza-López M, Meléndez-Alafort L, Croft BY, Ramírez FM, Padilla J. Labelling of Re-ABP with 188Re for bone pain palliation. Appl Radiat Isot. 2001 Mar;54(3):435-42. PubMed PMID: 11214878.

190: Oura S, Tanino H, Yoshimasu T, Sakurai T, Nakamura T, Kokawa Y, Matsuyama K, Ohta F, Naito Y. Bisphosphonate therapy for bone metastases from breast cancer: clinical results and a new therapeutic approach. Breast Cancer. 2000;7(4):307-10. PubMed PMID: 11114855.

191: Ohnishi T, Takeda E, Yogita S, Miyake H, Kinoshita T, Terashima Y, Matsumoto T, Tashiro S. Effects of alendronate on bone metastases and hypercalcemia after surgery for hepatocellular carcinoma. Jpn J Clin Oncol. 2000 Sep;30(9):410-3. PubMed PMID: 11095140.

192: Bernstein CN. Neoplastic and other complications of inflammatory bowel disease. Curr Gastroenterol Rep. 2000 Dec;2(6):451-9. Review. PubMed PMID: 11079046.

193: Drugs for prevention and treatment of postmenopausal osteoporosis. Med Lett Drugs Ther. 2000 Oct 16;42(1090):97-100. PubMed PMID: 11035622.

194: Basaria S, McCarthy EF, Belzberg AJ, Ball DW. Case of an ivory vertebra. J Endocrinol Invest. 2000 Sep;23(8):533-5. PubMed PMID: 11021770.

195: Tomlin JL, Sturgeon C, Pead MJ, Muir P. Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. Vet Rec. 2000 Jul 29;147(5):129-32. PubMed PMID: 10958534.

196: Mincey BA, Moraghan TJ, Perez EA. Prevention and treatment of osteoporosis in women with breast cancer. Mayo Clin Proc. 2000 Aug;75(8):821-9. Review. Erratum in: Mayo Clin Proc 2001 Jan;76(1):113. PubMed PMID: 10943237.

197: Kunisue H, Kurebayashi J, Sonoo H, Udagawa K, Yamamoto Y, Yamamoto S, Tanaka K, Shimozuma K. [A case of advanced breast cancer associated with humoral hypercalcemia that responded to medroxyprogesterone acetate and docetaxel]. Gan To Kagaku Ryoho. 2000 Jul;27(7):1043-6. Japanese. PubMed PMID: 10925692.

198: Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000 Jul 15;96(2):384-92. PubMed PMID: 10887096.

199: Oura S, Sakurai T, Yoshimura G, Tamaki T, Umemura T, Kokawa Y, Naito Y. [Pain relief with alendronate therapy in a breast cancer patient with bone metastasis]. Gan To Kagaku Ryoho. 2000 Apr;27(4):633-7. Japanese. PubMed PMID: 10791010.

200: Major PP, Lipton A, Berenson J, Hortobagyi G. Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer. 2000 Jan 1;88(1):6-14. Review. PubMed PMID: 10618600.

201: Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf. 1999 Nov;21(5):389-406. Review. PubMed PMID: 10554053.

202: Gatti D, Adami S. New bisphosphonates in the treatment of bone diseases. Drugs Aging. 1999 Oct;15(4):285-96. Review. PubMed PMID: 10582775.

203: Oura S, Sakurai T, Yoshimura G, Tamaki T, Umemura T, Kokawa Y. [Breast cancer with osteoblastic bone metastasis treated successfully with bisphosphonate: a case report]. Gan To Kagaku Ryoho. 1999 Oct;26(11):1651-5. Japanese. PubMed PMID: 10553426.

204: Oura S, Sakurai T, Yoshimura G, Tamaki T, Umemura T, Kokawa Y, Naito Y. [Study on the safety of rapid infusion and the efficacy of incadronate against bone metastasis of breast cancer]. Gan To Kagaku Ryoho. 1999 Oct;26(11):1623-8. Japanese. PubMed PMID: 10553421.

205: Oura S, Sakurai T, Yoshimura G, Tamaki T, Umemura T, Kokawa Y. [Effective alendronate therapy against a bone metastasis occurring during docetaxel therapy for breast cancer--a case report]. Gan To Kagaku Ryoho. 1999 Sep;26(10):1469-73. Japanese. PubMed PMID: 10500536.

206: Cohen H, Alferiev IS, Mönkkönen J, Seibel MJ, Pinto T, Ezra A, Solomon V, Stepensky D, Sagi H, Ornoy A, Patlas N, Hägele G, Hoffman A, Breuer E, Golomb G. Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate. Pharm Res. 1999 Sep;16(9):1399-406. PubMed PMID: 10496656.

207: Meiner SE. An expanding landscape. Osteoporosis. Treatment options today. Adv Nurse Pract. 1999 Jul;7(7):26-31, 80. Review. PubMed PMID: 10476099.

208: Makowski GS, Ramsby ML. Amorphous calcium phosphate-mediated binding of matrix metalloproteinase-9 to fibrin is inhibited by pyrophosphate and bisphosphonate. Inflammation. 1999 Aug;23(4):333-60. PubMed PMID: 10443797.

209: Teronen O, Heikkilä P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, Teronen A, Maisi P, Sorsa T. MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci. 1999 Jun 30;878:453-65. PubMed PMID: 10415748.

210: Lokeshwar BL. MMP inhibition in prostate cancer. Ann N Y Acad Sci. 1999 Jun 30;878:271-89. Review. PubMed PMID: 10415736.

211: Col NF, Pauker SG, Goldberg RJ, Eckman MH, Orr RK, Ross EM, Wong JB. Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women. Arch Intern Med. 1999 Jul 12;159(13):1458-66. PubMed PMID: 10399897.

212: Stearns ME, Wang M. Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice. Clin Exp Metastasis. 1998 Nov;16(8):693-702. PubMed PMID: 10211982.

213: Sadamori N, Taguchi J, Imaizumi Y, Tsushima H, Yoshida S, Hata T, Soda H, Tomonaga M. Efficacy of bisphosphonate for hypercalcemia in patients with adult T-cell leukemia. Leuk Res. 1999 Feb;23(2):199-200. PubMed PMID: 10071137.

214: Khovidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med. 1999 Mar 2;130(5):431-9. Review. PubMed PMID: 10068418.

215: Oura S, Sakurai T, Yoshimura G, Tamaki T, Umemura T, Kokawa Y. [A study of the safety of rapid infusion of alendronate]. Gan To Kagaku Ryoho. 1999 Feb;26(3):345-51. Japanese. PubMed PMID: 10065098.

216: Dooley M, Balfour JA. Ibandronate. Drugs. 1999 Jan;57(1):101-8; discussion 109-10. Review. PubMed PMID: 9951955.

217: Robb-Nicholson C. I am 51 years old, perimenopausal, have irritable bowel syndrome and a family history of breast cancer, and am told my bones are thinning. These conditions would seem to rule out my use of estrogen or Fosamax. I weight train and take 1,500 mg of calcium a day to stave off osteoporosis. What's left? Harv Womens Health Watch. 1998 Nov;6(3):8. PubMed PMID: 9814138.

218: Phillips E, Knowles S, Weber E, Shear NH. Skin reactions associated with bisphosphonates: a report of 3 cases and an approach to management. J Allergy Clin Immunol. 1998 Oct;102(4 Pt 1):697-8. PubMed PMID: 9802383.

219: Andrews WC. What's new in preventing and treating osteoporosis? Postgrad Med. 1998 Oct;104(4):89-92, 95-7. Review. PubMed PMID: 9793557.

220: Willhite L. Osteoporosis in women: prevention and treatment. J Am Pharm Assoc (Wash). 1998 Sep-Oct;38(5):614-23; quiz 623-4. Review. PubMed PMID: 9782696.

221: Lteif AN, Zimmerman D. Bisphosphonates for treatment of childhood hypercalcemia. Pediatrics. 1998 Oct;102(4 Pt 1):990-3. Review. PubMed PMID: 9755274.

222: Lappe JM, Tinley ST. Prevention of osteoporosis in women treated for hereditary breast and ovarian carcinoma: a need that is overlooked. Cancer. 1998 Sep 1;83(5):830-4. PubMed PMID: 9731880.

223: Stearns ME. Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells. Clin Exp Metastasis. 1998 May;16(4):332-9. PubMed PMID: 9626812.

224: Mahon SM. Case in point. Counseling about hormone replacement therapy. Oncol Nurs Forum. 1998 May;25(4):663-4. PubMed PMID: 9599344.

225: Takahashi K, Shirahata A, Fukushima S, Kokubo S, Teramura K, Usuda S. Effects of YM175, a new-generation bisphosphonate, on hypercalcemia induced by tumor-derived bone resorbing factors in rats. Jpn J Pharmacol. 1998 Feb;76(2):155-63. PubMed PMID: 9541278.

226: Aaseth J, Syversen U, Førre O. [Diphosphonates--pharmacology and clinical use]. Tidsskr Nor Laegeforen. 1998 Mar 10;118(7):1064-6. Norwegian. PubMed PMID: 9531831.

227: Gibaldi M. Prevention and treatment of osteoporosis: does the future belong to hormone replacement therapy? J Clin Pharmacol. 1997 Dec;37(12):1087-99. Review. PubMed PMID: 9506003.

228: Nakanishi Y, Takayama K, Hara N. [Paraneoplastic syndrome]. Gan To Kagaku Ryoho. 1997 Oct;24 Suppl 3:445-50. Review. Japanese. PubMed PMID: 9369921.

229: Adami S. Bisphosphonates in prostate carcinoma. Cancer. 1997 Oct 15;80(8 Suppl):1674-9. Review. PubMed PMID: 9362435.

230: Patel S. Current and potential future drug treatments for osteoporosis. Ann Rheum Dis. 1996 Oct;55(10):700-14. Review. PubMed PMID: 8984934; PubMed Central PMCID: PMC1010285.

231: Diener KM. Bisphosphonates for controlling pain from metastatic bone disease. Am J Health Syst Pharm. 1996 Aug 15;53(16):1917-27. Review. PubMed PMID: 8862204.

232: van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Löwik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest. 1996 Aug 1;98(3):698-705. PubMed PMID: 8698861; PubMed Central PMCID: PMC507479.

233: Body JJ, Coleman RE, Piccart M. Use of bisphosphonates in cancer patients. Cancer Treat Rev. 1996 Jul;22(4):265-87. Review. PubMed PMID: 9025784.

234: Endo N, Rutledge SJ, Opas EE, Vogel R, Rodan GA, Schmidt A. Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates. J Bone Miner Res. 1996 Apr;11(4):535-43. PubMed PMID: 8992885.

235: Horan AH. Re: Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer. J Urol. 1996 Apr;155(4):1395. PubMed PMID: 8632592.

236: Stearns ME, Wang M. Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis. 1996;16(3):116-31. PubMed PMID: 9186547.

237: Contradictory hormone studies renew debate over breast cancer link. Am J Health Syst Pharm. 1995 Oct 1;52(19):2066, 2076. PubMed PMID: 8535935.

238: Koyano H, Schimizu T, Shishiba Y. The bisphosphonate dilemma. J Nucl Med. 1995 Apr;36(4):705-6. PubMed PMID: 7699469.

239: Sato K, Toraya S, Shiratori K, Kasagi Y, Mandai Y, Miyamoto T, Fukuda I, Kasono K, Demura H, Obara T. Appropriate intravenous doses of L-thyroxine and magnesium in a thyroidectomized patient with thyroid and parathyroid carcinomas receiving total parenteral nutrition during acute necrotizing pancreatitis. Intern Med. 1995 Mar;34(3):176-82. PubMed PMID: 7787323.

240: Singer FR, Minoofar PN. Bisphosphonates in the treatment of disorders of mineral metabolism. Adv Endocrinol Metab. 1995;6:259-88. Review. PubMed PMID: 7671099.

241: Tohkin M, Kakudo S, Kasai H, Arita H. Comparative study of inhibitory effects by murine interferon gamma and a new bisphosphonate (alendronate) in hypercalcemic, nude mice bearing human tumor (LJC-1-JCK). Cancer Immunol Immunother. 1994 Sep;39(3):155-60. PubMed PMID: 7522963.

242: Plosker GL, Goa KL. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs. 1994 Jun;47(6):945-82. Review. PubMed PMID: 7521833.

243: Budayr AA, Zysset E, Jenzer A, Thiébaud D, Ammann P, Rizzoli R, Jaquet-Müller F, Bonjour JP, Gertz B, Burckhardt P, et al. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein. J Bone Miner Res. 1994 Apr;9(4):521-6. PubMed PMID: 8030440.

244: Nussbaum SR, Warrell RP Jr, Rude R, Glusman J, Bilezikian JP, Stewart AF, Stepanavage M, Sacco JF, Averbuch SD, Gertz BJ. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. J Clin Oncol. 1993 Aug;11(8):1618-23. PubMed PMID: 8336198.

245: Zysset E, Ammann P, Jenzer A, Gertz BJ, Portmann L, Rizzoli R, Jaquet-Müller F, Pryor-Tillotson S, Bonjour JP, Burckhardt P. Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy. Bone Miner. 1992 Sep;18(3):237-49. PubMed PMID: 1392697.

246: Nemoto R, Satou S, Mochizuki T, Okabe K. Response of MBT-2 bladder carcinoma-induced osteolysis to various agents. Cancer. 1992 May 1;69(9):2316-21. PubMed PMID: 1562978.

247: Rizzoli R, Buchs B, Bonjour JP. Effect of a single infusion of alendronate in malignant hypercalcaemia: dose dependency and comparison with clodronate. Int J Cancer. 1992 Mar 12;50(5):706-12. PubMed PMID: 1531972.

248: Mitlak BH, Hutchison JS, Kaufman SD, Nussbaum SR. Parathyroid hormone-related peptide mediates hypercalcemia in an islet cell tumor of the pancreas. Horm Metab Res. 1991 Jul;23(7):344-6. PubMed PMID: 1663481.

249: Nemoto R, Satou S, Miyagawa I, Koiso K. Inhibition by a new bisphosphonate (AHBuBP) of bone resorption induced by the MBT-2 tumor of mice. Cancer. 1991 Feb 1;67(3):643-8. PubMed PMID: 1898709.

250: Warrell RP Jr. Hypercalcemia and bone metastases in breast cancer. Curr Opin Oncol. 1990 Dec;2(6):1097-103. Review. PubMed PMID: 2151596.

251: Nemoto R, Sato S, Nishijima Y, Miyakawa I, Koiso K, Harada M. Effects of a new bisphosphonate (AHBuBP) on osteolysis induced by human prostate cancer cells in nude mice. J Urol. 1990 Sep;144(3):770-4. PubMed PMID: 2117674.

252: Attardo-Parrinello G, Merlini G, Crema F, Fiorentini ML, Mazzone A, Cotti-Piccinelli E. [Combined treatment, polychemotherapy and amino-hydroxybutylidene-diphosphonate, of a patient with multiple myeloma: remission and long survival]. Medicina (Firenze). 1988 Jul-Sep;8(3):318-20. Italian. PubMed PMID: 3231044.

253: Attardo-Parrinello G, Crema F, Merlini G, Spaghi A, Fiorentini ML. [Use of diphosphonates in the treatment of hypercalcemia in multiple myeloma: efficacy of 4-amino-hydroxybutylidene-1,1-bisphosphonate (AHButBP)]. Medicina (Firenze). 1988 Jan-Mar;8(1):75-6. Italian. PubMed PMID: 3226251.

254: Kozak S, Rizzoli R, Trechsel U, Fleisch H. Effect of a single injection of two new bisphosphonates on the hypercalcemia and hypercalciuria induced by Walker carcinosarcoma 256/B in thyroparathyroidectomized rats. Cancer Res. 1987 Dec 1;47(23):6193-7. PubMed PMID: 3677071.

255: Attardo-Parrinello G, Merlini G, Pavesi F, Crema F, Fiorentini ML, Ascari E. Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate. Arch Intern Med. 1987 Sep;147(9):1629-33. PubMed PMID: 2957971.